KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC
Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.
Read More
TKI Monotherapy Data in Non–Clear Cell RCC
Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.
Read More
Overview of Non–Clear Cell RCC
The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.
Read More
Clinical Insights on Belzutifan in Advanced RCC
Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.
Read More
Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC
Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.
Read More
CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC
Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.
Read More
Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC
David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.
Read More
LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research
Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.
Read More
Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC
Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.
Read More
CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC
The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.
Read More
Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.
Read More
LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis
Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.
Read More
Recent Subgroup Analyses from the CLEAR study in Advanced RCC
Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.
Read More
CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC
Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.
Read More
Long-Term Follow-Up from CheckMate 214 in Advanced RCC
The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.
Read More
First-Line Treatments for Advanced Clear Cell RCC
A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.
Read More
Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment
Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Read More
Triple Combination Therapies in RCC: Clinical Trial Insights
Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Read More
Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing
Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
Read More
Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma
Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.
Read More
Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC
Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).
Read More
Sequencing and Second-Line Therapy in RCC: Patient Scenario
Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.
Read More
Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.
Read More
Comparing Treatment Combinations in Renal Cell Carcinoma
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.
Read More
Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma
Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.
Read More
Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen
Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.
Read More
Imaging and Staging Considerations in Renal Cell Carcinoma
Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.
Read More
Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion
Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.
Read More
Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification
Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.
Read More